IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11845963 B1

PDFFull Text
Date of Patent:
Dec. 19, 2023

Filed:

Jan. 19, 2018

Hsd17b13 variants and uses thereof

Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Noura S. Abul-Husn, Tarrytown, NY (US);

Omri Gottesman, Tarrytown, NY (US);

Alexander Li, Tarrytown, NY (US);

Xiping Cheng, Tarrytown, NY (US);

Yurong Xin, Tarrytown, NY (US);

Jesper Gromada, Tarrytown, NY (US);

Frederick E. Dewey, Tarrytown, NY (US);

Aris Baras, Tarrytown, NY (US);

Alan Shuldiner, Tarrytown, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorney:

Armstrong Teasdale LLP

Primary Examiner:

Stephen T Kapushoc

Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12N 9/04 (2006.01); C12N 15/113 (2010.01); C12Q 1/6883 (2018.01); A61K 31/713 (2006.01); G01N 33/50 (2006.01); C12Q 1/32 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6876 (2018.01); A61K 47/61 (2017.01); A61P 1/16 (2006.01); A61K 38/44 (2006.01); A61K 38/46 (2006.01); C12N 9/22 (2006.01); C12N 9/96 (2006.01); C12N 15/11 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/0006 (2013.01); A61K 31/713 (2013.01); A61K 38/443 (2013.01); A61K 38/465 (2013.01); A61K 47/61 (2017.08); A61P 1/16 (2018.01); C12N 9/22 (2013.01); C12N 9/96 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12Q 1/32 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6876 (2013.01); C12Q 1/6883 (2013.01); C12Y 101/01051 (2013.01); C12Y 101/01062 (2013.01); G01N 33/5067 (2013.01); A61K 48/00 (2013.01); A61K 48/0066 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2320/34 (2013.01); C12N 2800/24 (2013.01); C12N 2800/80 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4704 (2013.01); G01N 2800/085 (2013.01);
Abstract

Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

Find Patent Forward Citations

Loading…